第58届美国血液病年会关于慢性粒细胞白血病的研究精选

桂瑞瑞; 张龚莉; 宋永平

doi:10.13201/j.issn.1004-2806.2018.01.018

第58届美国血液病年会关于慢性粒细胞白血病的研究精选

- 郑州大学附属肿瘤医院血液科、河南省肿瘤医院血液科、河南省血液病研究所(郑州, 450008)

详细信息

通讯作者: 宋永平,E-mail:songyongping@medmail.com.cn

中图分类号: R733.72

收稿日期: 2017-01-24

New advances in the study of chronic myeloid leukemia at the 58th American Society of Hematology

More Information

Corresponding author: SONG Yongping, E-mail: songyongping@medmail.com.cn

Received Date: 24 January 2017

摘要

- 慢性粒细胞白血病 /
- 新进展 /
- 酪氨酸激酶抑制剂
Abstract: With the more experiences of tyrosine kinase inhibitors (TKI) treatment of chronic myeloid leukemia (CML),we summarized a lot of new ideas and treatment countermeasures to the disease.This annual meeting centered on the following topics,such as the recent advances in the treatment of CML,optimizing the TKI drug conversion and the safety of TKI treatment and the sensation of TKI.Anyway,we should look forward to achieve even greater success in the treatment of CML and sum up the more precise and scientific treatment.
- chronic myeloid leukemia /
- new progress /
- tyrosine kinase inhibitors

HTML全文

参考文献(30)

[1]	Kadowaki N, Kawaguchi T, Kuroda J, et al.Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2years:A multicenter phase 2stop Nilotinib (Nilst) trial[C].ASH, 2016, abstract 790.
[2]	Shah NP, Paquette R, Müller MC, et al.Treatmentfree remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to Dasatinib-the Dasfree study[C].ASH, 2016, abstract 1895.
[3]	Kumagai T, Nakaseko C, Nishiwaki K, et al.Discontinuation of Dasatinib after deep molecular response for over 2years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation:A prospective, multicenter Japanese trial (D-STOP Trial)[C].ASH, 2016, abstract 791.
[4]	Hughes A, Clarson J, White DL, et al.Enhanced natural killer and cytotoxic T lymphocyte responses, with decreased monocytic myeloid derived suppressor cells may promote treatment free remission in chronic myeloid leukaemia patients following tyrosine kinase inhibitor cessation[C].ASH, 2016, abstract 1122.
[5]	Mahon FX, Richte J, Guilhot J, et al.Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response:Results of the Euro-Ski Trial[C].ASH, 2016, abstract787.
[6]	Pagliardini T, Franck E, Giraudie S, et al.Second TKIdiscontinuation in CML patients that failed first discontinuation and subsequently regained deep molecular response after TKI re-challenge[C].ASH, 2016, abstract 788.
[7]	Goldberg S, Michallet M, Hehlmann R, et al.Tyrosine kinase inhibitor switching patterns during the first 12months in simplicity, an observational study of chronic-phase chronic myeloid leukemia patients in routine clinical practice[C].ASH, 2016, abstract 937.
[8]	Huang XJ, Jiang Q, Hu JD, et al.Long-term safety of dasatinib in chinese chronic phase chronic myeloid leukemia patients with imatinib-resistance or-intolerance:Results from a 6-year follow-up of a multicenter phase II study[C].ASH, 2016, abstract 1928.
[9]	Yeung DT, Mbbs BSc.Upfront imatinib with selective early switching to nilotinib leads to excellent achievement of deep molecular response in chronic phase CML:5year (Final) analysis of the TIDEL-II study[C].ASH, 2016, abstract 939.
[10]	Shibayama H, Kawaguchi T, Kuroda J, et al.Safety and efficacy of a switch to nilotinib in patients with CML-CP showing MMR to imatinib:Results of a multicenter phase II trial (NILSw Trial)[C].ASH, 2016, abstract 1941.
[11]	Gugliotta G, Castagnetti F, Breccia M, et al.Impact of age on efficacy, safety, and long-term outcome of chronic myeloid leukemia patients treated in first-line with nilotinib:An analysis of the Gimema CML Working Party[C].ASH, 2016, abstract 3068.
[12]	Miyamura K, Ohtake S, Ohnishi K, et al.Phase IIIrandomized study of imatinib therapy in chronic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSGCML207study)[C].ASH, 2016, abstract 941.
[13]	Ilander M, Lhteenmki H, Stromberg UO, et al.Effects of dasatinib and interferon-αcombination treatment on the immune system in CML[C].ASH, 2016, abstract 627.
[14]	Ghorab AN, Kantarjian HM, Jain P, et al.Cryptic philadelphia chromosome in newly diagnosed chronic phase CML (CML-CP):Clinical characteristics and treatment outcome after treatment with 5TKI modalities[C].ASH, 2016, abstract 3082.
[15]	Turner KA, Rothe K, Woolfson A, et al.Drug-insensitive CML stem/progenitor cells highly express key regulators of the hedgehog pathway and inhibition of the hedgehog pathway enhances their response to TKItreatment[C].ASH, 2016, abstract 4236.
[16]	Ashizawa AT, Ohanian M, Cortes JE.BP1001, a novel therapeutic for chronic myelogenous leukemia[C].ASH, 2016, abstract 4239.
[17]	Nteliopoulos G, Bazeos A, Gerrard G, et al.Somatic mutations in epigenetic modifiers identified using next generation sequencing (NGS) in diagnostic samples of CML-CP can predict poor outcome on imatinib which is abrogated by frontline 2G-TKI therapy[C].ASH, 2016, abstract 1223.
[18]	Alhuraiji A, Kantarjian HM, Jabbour EJ, et al.Prognostic value of clonal evolution at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors[C].ASH, 2016, abstract 3064.
[19]	Castagnetti F, Gugliotta G, Breccia M, et al.Prognostic value of BCR-ABL1transcript type in chronic myeloid leukemia patients treated frontline with nilotinib[C].ASH, 2016, abstract 3070.
[20]	Than H, Lye WK, Seow CH, et al.Genetic profiling augments prognostic value of the EUTOS long-term survival score for disease-specific mortality in imatinib-treated Asian chronic myeloid leukaemia patients[C].ASH, 2016, abstract 3077.
[21]	Hara R, Onizuka M, Matsusita E, et al.NKG2Dgene polymorphism is associated with disease control of chronic myeloid leukemia by dasatinib[C].ASH, 2016, abstract 3091.
[22]	Yoshida C, Iriyama N, Najima Y, et al.Association of peripheral regulatory T cells with achievement of deep molecular response in newly diagnosed chronic phase chronic myeloid leukemia treated with dasatinib-the final results of D-first study[C].ASH, 2016, Abstract1916.
[23]	Klil-Drori AJ, Azoulay L, Yin H, et al.Timely molecular monitoring and achievement of major molecular response in chronic myeloid leukemia[C].ASH, 2016, abstract 3072.
[24]	Sam PY, Ahaneku H, Nogueras-Gonzalez GM, et al.Cardiovascular events among patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors[C].ASH, 2016, abstract 1919.
[25]	Franklin M, Burns L, Perez S, et al.Incidence of type II diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first or second line therapy for chronic myelogenous leukemia[C].ASH, 2016, abstract 4766.
[26]	Zhu Y, Li JY, Qiao C, et al.PFKFB3is a crucial target in the treatment of tyrosine kinase inhibitor resistant chronic myelogenous leukemia[C].ASH, 2016, abstract 3936.
[27]	Wang FJ, Niu T.A potent small molecule compound might overcome high level drug resistant mutations of BCR-ABL1[C].ASH, 2016, abstract 3942.
[28]	Liu B, Wang Y, Wei H, et al.Impact of additional chromosomal abnormalities in Philadelphia-positive clone on prognosis of CML patients treated with tyrosine kinase inhibitors[C].ASH, 2016, abstract 1926.
[29]	Jiang Q, Huang XJ, Yu L, et al.Co-morbidity profile influences work, daily life and health-related qualityof-life in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy[C].ASH, 2016, abstract 1927.
[30]	Jiang Q, Yu L, Gale RP, et al.Patients'and physicians'concerns about tyrosine kinase-inhibitor therapy in chronic myeloid leukemia[C].ASH, 2016, abstract3092.